Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial

Table 4 Frequency distribution of clinical signs and symptoms following 48 h of treatment

Variable	Groups	Value	P-value
Fever	Amikacin	0	0.24 *
Fever	Meropenem	3 (9.1%)	0.24 *
Dysuria	Amikacin	4 (14.3%)	1 *
Dysuria	Meropenem	5 (15.2%)	1 *
Frequent urination	Amikacin	3 (10.7%)	0.71 *
Frequent urination	Meropenem	5 (15.2%)	0.71 *
Abdominal pain	Amikacin	1 (3.7%)	0.2 *
Abdominal pain	Meropenem	5 (15.2%)	0.2 *
Flank pain	Amikacin	3 (10.7%)	0.2 *
Flank pain	Meropenem	8 (24.2%)	0.2 *
Suprapubic pain	Amikacin	6 (21.4%)	0.49*
Suprapubic pain	Meropenem	4 (12.1%)	0.49*
Costovertebral angle tenderness (CVAT)	Amikacin	0	-
Costovertebral angle tenderness (CVAT)	Meropenem	0	-

ISSN: 1756-0500